GlassScriptPhysician profile
Stephanie P Green
NPI 1245720705
$6,942.59
in general payments reported to CMS, 2019-2025
29 companies · $4,050 in 2025
The $4,050 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $771 · 2024: $2,121 · 2025: $4,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,217 · Travel and Lodging: $702 · Education: $23.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,216.96 |
| Travel and Lodging | $702.09 |
| Education | $23.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,987.37 | 2023-2025 | Xeomin |
| Insulet Corporation | $1,793.07 | 2023-2025 | Omnipod |
| Amgen INC. | $533.60 | 2024-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $522.69 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $322.53 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $228.66 | 2024-2025 | |
| Radius Health, INC. | $202.08 | 2023-2025 | Tymlos |
| Novo Nordisk INC | $139.99 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $137.43 | 2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $117.42 | 2024-2025 | Isturisa, Signifor Lar |
| Astrazeneca Pharmaceuticals LP | $101.86 | 2024-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.57 | 2024-2025 | Jardiance |
| Almatica Pharma LLC | $75.66 | 2024-2025 | Teriparatide |
| Tandem Diabetes Care, INC. | $75.29 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $71.54 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $67.49 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $59.34 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $58.91 | 2025 | |
| Sandoz INC. | $57.44 | 2025 | Hyrimoz |
| Antares Pharma, INC. | $55.00 | 2024-2025 | Xyosted, Tlando |
| Dexcom, INC. | $49.83 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $43.27 | 2024-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $37.89 | 2025 | Strensiq |
| Halozyme INC | $22.06 | 2023 | |
| Alvogen INC | $21.87 | 2025 | Teriparatide |
| Kyowa Kirin, INC. | $21.37 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.78 | 2024 | |
| Abbott Laboratories | $16.94 | 2024 | Freestyle Libre 3 |
| Beta Bionics, INC. | $15.64 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.